Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.67 |
| ▸ | ANPEP | P15144 | 8/20 | 0.67 |
| ▸ | PEPD | P12955 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10027150 | 1.00 | MMP2 (0.67) | MMP2ANPEPPEPDATMALDH1A1 | |
| SCHEMBL5494889 | 1.00 | MMP2 (0.67) | MMP2ANPEPPEPDATMALDH1A1 | |
| SCHEMBL3788772 | 0.85 | MMP2 (0.72) | MMP2ANPEPPEPDATMALDH1A1 | |
| SCHEMBL3783083 | 0.85 | MMP2 (0.72) | MMP2ANPEPPEPDATMALDH1A1 | |
| SCHEMBL3788774 | 0.85 | MMP2 (0.72) | MMP2ANPEPPEPDATMALDH1A1 | |
| SCHEMBL10793356 | 0.85 | MMP2 (0.72) | MMP2ANPEPPEPDATMALDH1A1 | |
| SCHEMBL3784082 | 0.85 | MMP2 (0.72) | MMP2ANPEPPEPDATMALDH1A1 | |
| SCHEMBL3783080 | 0.85 | MMP2 (0.72) | MMP2ANPEPPEPDATMALDH1A1 | |
| SCHEMBL3789111 | 0.85 | MMP2 (0.72) | MMP2ANPEPPEPDATMALDH1A1 | |
| SCHEMBL12395381 | 0.84 | PEPD (0.55) | MMP2ANPEPPEPDALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2014-10-16 | — | — | US | disclosed |
| US-20120022040-A1 | ANTIMICROBIALS | AMPLYX PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | API5, BIRC5, BAD | MMP2 2035/4885ANPEP 1414/4885PEPD 1117/4885 |
| US-20120022040-A1 | ANTIMICROBIALS | PAM, MPO, OXA1L | MMP2 828/4885ANPEP 75/4885PEPD 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.